Japanese Insurance Stock News

TSE:6856
TSE:6856Electronic

Does Rising Activism and AGM Pushback Reshape the Governance Case for HORIBA (TSE:6856)?

At HORIBA’s 2026 AGM held earlier this year, Chairman Atsushi Horiba was reappointed with only 74.4% shareholder support, highlighting concerns over governance, capital allocation, and portfolio oversight. The continued activism of 9.90% shareholder Oasis Management, pressing for clearer portfolio review criteria and stronger board independence, underlines mounting pressure for concrete governance reforms. We will now examine how rising shareholder pressure for clearer portfolio...
TSE:3282
TSE:3282Residential REITs

A Look At Comforia Residential REIT (TSE:3282) Valuation After New Positive Impact Financing And Updated Forecasts

Comforia Residential REIT (TSE:3282) just laid out a clearer picture of its balance sheet and payouts, pairing fresh long term borrowing plans under Positive Impact Finance schemes with updated earnings and dividend forecasts. See our latest analysis for Comforia Residential REIT. Even with a 1 year total shareholder return of 26.51%, recent momentum has cooled, with a 1 month share price return showing a 3.42% decline and a 1 day move of 0.81% decline as investors digest the new financing...
TSE:4716
TSE:4716Software

Oracle Japan (TSE:4716) Net Margin Softness Tests Bullish Earnings Narratives

Oracle Corporation Japan (TSE:4716) Q3 2026 Earnings Snapshot Oracle Corporation Japan (TSE:4716) has put another solid quarter on the board, with recent fiscal period revenue running between ¥61,380 million and ¥70,618 million and basic EPS ranging from about ¥108.96 to ¥123.96, backed by trailing twelve month EPS of ¥478.63 and net income of ¥61,296 million. Over the past six reported quarters, the company has seen revenue move from ¥61,380 million in Q2 2025 to ¥68,402 million in Q2 2026,...
TSE:6787
TSE:6787Electronic

Global's March 2026 Stock Selections For Potential Value Opportunities

Amid a backdrop of heightened geopolitical tensions and persistent inflation concerns, global markets have experienced notable volatility, with major indices such as the Dow Jones Industrial Average and the Nasdaq Composite posting declines. As central banks signal caution and energy prices surge, investors are increasingly focused on identifying undervalued stocks that may offer potential value opportunities in this uncertain environment. In such conditions, a good stock is often...
TSE:6902
TSE:6902Auto Components

Is It Time To Revisit DENSO (TSE:6902) After Recent Share Price Weakness

If you are wondering whether DENSO's current share price reflects its true worth, this breakdown will help you connect the dots between price, fundamentals and valuation. The stock most recently closed at ¥1,928.5, with returns of 0.7% over 7 days, a 13.2% decline over 30 days, an 11.6% decline year to date, 0.0% over 1 year, 12.7% over 3 years and 21.4% over 5 years. These moves sit against an ongoing flow of sector and macro headlines that keep reshaping how investors think about auto...
TSE:7974
TSE:7974Entertainment

Assessing Nintendo (TSE:7974) Valuation After Recent Share Price Swings And Console Outlook

Why Nintendo Stock Is Back on Investors’ Radar Nintendo (TSE:7974) has moved back into focus after recent share price swings, with the stock showing a mix of short term pressure and longer term gains that raises questions about how investors are pricing its gaming business. See our latest analysis for Nintendo. Recent trading has been choppy, with a 7 day share price return of 7.79% and a 90 day share price decline of 16.85%, set against a 3 year total shareholder return of 84.68%. This...
TSE:4519
TSE:4519Pharmaceuticals

Chugai Pharmaceutical (TSE:4519) Is Down 5.8% After Dropping SMA Drug But Keeping Obesity Bet

Earlier this week, Chugai Pharmaceutical reported that Roche will discontinue development of GYM329 (emugrobart) for spinal muscular atrophy and facioscapulohumeral muscular dystrophy after Phase II/III data showed insufficient functional benefits despite a favorable safety profile. Because emugrobart development will continue in obesity, where the disease biology and myostatin levels differ from neuromuscular conditions, the program’s risk-reward profile shifts toward metabolic disease...